U.S. Atherectomy Devices Market Size, Share & Trends Analysis Report By Type (Laser, Directional, Rotational, Orbital), By End Use (Office-based Labs, Out-patient Facility, In-patient Facility), And Segment Forecasts, 2019 - 2025
This report can be delivered to the clients within Immediate
The U.S. atherectomy devices market size is expected to reach USD 626.1 million by 2025 expanding at a CAGR of 6.6%, according to a new report by Grand View Research, Inc. The regional market is expected to witness lucrative growth due to the rising prevalence of target diseases and preference for endovascular procedures. Moreover, rising demand for minimally invasive procedure will boost the market growth. Such procedures are less painful and allow quicker recovery than invasive procedures.
Other advantages, such as higher patient satisfaction owing to fewer incision wounds, few post-surgical complications, and low mortality rates, are also driving the atherectomy devices market growth. Technological advancements allowing early diagnosis are also likely to augment the market growth in the near future. For instance, in January 2017, Medtronic received CE mark approval for HawkOne directional atherectomy system for treating patients suffering from Peripheral Artery Disease (PAD).
Further key findings from the study suggest:
Adoption of atherectomy increased sharply in the past due to increased reimbursement for the procedure. According to Elsevier Inc., there was a rise in atherectomy volume for Medicare beneficiaries to 76% in 2011–2015
Directional atherectomy devices accounted for the largest share of the market in 2017 as the device exhibited 95% successful removal of lesions and 94% of patients did not exhibit adverse effects
Office-Based Labs (OBLs) is anticipated to be the fastest-growing segment in the forecast period due to a greater number of Peripheral Vascular Interventional (PVI) procedures being performed in this setting
In addition, lesser number of complications and follow-up procedures lowers the cost and increases the adoption of new technologies delivering better health outcomes, which is anticipated to propel the market growth in the coming years
Several ongoing trials and their positive results facilitate penetration of novel technologies. For instance, in March 2017, Cardiovascular Systems, Inc. enrolled for its latest clinical trial, ECLIPSE, which was perceived to be the largest trial conducted to study coronary atherectomy
Some of the key companies are Spectranetics Corp.; Boston Scientific Corp.; Cardinal Health, Inc.; Straub Medical AG; Terumo Medical Corp.; Cardiovascular Systems, Inc.; Medtronic PLC; Avinger, Inc.; ST. JUDE MEDICAL, Inc.
The U.S. atherectomy devices market size is expected to reach USD 626.1 million by 2025 expanding at a CAGR of 6.6%, according to a new report by Grand View Research, Inc. The regional market is expected to witness lucrative growth due to the rising prevalence of target diseases and preference for endovascular procedures. Moreover, rising demand for minimally invasive procedure will boost the market growth. Such procedures are less painful and allow quicker recovery than invasive procedures.
Other advantages, such as higher patient satisfaction owing to fewer incision wounds, few post-surgical complications, and low mortality rates, are also driving the atherectomy devices market growth. Technological advancements allowing early diagnosis are also likely to augment the market growth in the near future. For instance, in January 2017, Medtronic received CE mark approval for HawkOne directional atherectomy system for treating patients suffering from Peripheral Artery Disease (PAD).
Further key findings from the study suggest:
Adoption of atherectomy increased sharply in the past due to increased reimbursement for the procedure. According to Elsevier Inc., there was a rise in atherectomy volume for Medicare beneficiaries to 76% in 2011–2015
Directional atherectomy devices accounted for the largest share of the market in 2017 as the device exhibited 95% successful removal of lesions and 94% of patients did not exhibit adverse effects
Office-Based Labs (OBLs) is anticipated to be the fastest-growing segment in the forecast period due to a greater number of Peripheral Vascular Interventional (PVI) procedures being performed in this setting
In addition, lesser number of complications and follow-up procedures lowers the cost and increases the adoption of new technologies delivering better health outcomes, which is anticipated to propel the market growth in the coming years
Several ongoing trials and their positive results facilitate penetration of novel technologies. For instance, in March 2017, Cardiovascular Systems, Inc. enrolled for its latest clinical trial, ECLIPSE, which was perceived to be the largest trial conducted to study coronary atherectomy
Some of the key companies are Spectranetics Corp.; Boston Scientific Corp.; Cardinal Health, Inc.; Straub Medical AG; Terumo Medical Corp.; Cardiovascular Systems, Inc.; Medtronic PLC; Avinger, Inc.; ST. JUDE MEDICAL, Inc.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information Procurement
1.2 Data Analysis
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing prevalence of target diseases
3.1.1.2 Preference to minimally invasive procedures
3.1.2 Market restraint analysis
3.1.2.1 Lack of level 1 evidence for atherectomy
3.1.2.2 Lack of technical training for the procedure
3.1.2.3 Significant adoption of alternative therapies
3.2 Penetration & Growth Prospects Mapping
3.3 U.S. Atherectomy Devices Market - PESTLE Analysis
3.4 Industry Analysis - Porter’s
3.5 U.S. Atherectomy Devices: Regulatory Scenario
3.6 U.S. Atherectomy Devices Market: Reimbursement Scenario
3.7 Key Clinical Trials & Studies
3.7.1 Opinions/Views on Key Clinical Trials and Their Impact on the Market and Customer
3.8 U.S. Peripheral Atherectomy: Number of Procedures
CHAPTER 4 U.S. ATHERECTOMY DEVICES MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1 U.S. Atherectomy Devices Market: Type Movement Analysis
4.2 Directional Atherectomy Devices
4.2.1 Directional atherectomy devices market, 2014 - 2025 (USD Million)
4.3 Rotational Atherectomy Devices
4.3.1 Rotational atherectomy market, 2014 - 2025 (USD Million)
4.4 Orbital Atherectomy Devices
4.4.1 Orbital atherectomy devices market, 2014 - 2025 (USD Million)
4.5 Laser Atherectomy Devices
4.5.1 Laser atherectomy devices market, 2014 - 2025 (USD Million)
CHAPTER 5 U.S. ATHERECTOMY DEVICES MARKET: END USE ESTIMATES & TREND ANALYSIS
5.1 U.S. Atherectomy Devices Market: End Use Movement Analysis
5.2 In-Patient Facility
5.2.1 In-patient facility market, 2014 - 2025 (USD Million)
5.3 Office-Based Labs (OBLs)
5.3.1 Office-based labs (OBLs) market, 2014 - 2025 (USD Million)
5.4 Out-Patient facility
5.4.1 Out-patient facility, 2014 - 2025 (USD Million)
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 Strategy Framework
6.2 Competitive Landscape: Market Position Analysis
6.3 Company Profiles
6.3.1 Boston Scientific Corporation
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 SWOT analysis
6.3.1.4 Product benchmarking
6.3.1.5 Strategic initiatives
6.3.2 Cardiovascular Systems, Inc.
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 SWOT analysis
6.3.2.4 Product benchmarking
6.3.2.5 Strategic initiatives
6.3.3 Medtronic
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 SWOT analysis
6.3.3.4 Product benchmarking
6.3.3.5 Strategic initiatives
6.3.4 Spectranetics
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 SWOT analysis
6.3.4.4 Product benchmarking
6.3.4.5 Strategic initiatives
6.3.5 Avinger
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 ST. JUDE MEDICAL
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 SWOT analysis
6.3.6.4 Product benchmarking
6.3.7 Cardinal Health (Cordis)
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 SWOT analysis
6.3.7.4 Product benchmarking
6.3.7.5 Strategic initiatives
6.3.8 Terumo Medical Corporation
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 SWOT analysis
6.3.8.4 Product benchmarking
6.3.8.5 Strategic initiatives
CHAPTER 7 RECOMMENDATIONS
7.1 KOL Views
7.2 Recommendations
1.1 Information Procurement
1.2 Data Analysis
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation and Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing prevalence of target diseases
3.1.1.2 Preference to minimally invasive procedures
3.1.2 Market restraint analysis
3.1.2.1 Lack of level 1 evidence for atherectomy
3.1.2.2 Lack of technical training for the procedure
3.1.2.3 Significant adoption of alternative therapies
3.2 Penetration & Growth Prospects Mapping
3.3 U.S. Atherectomy Devices Market - PESTLE Analysis
3.4 Industry Analysis - Porter’s
3.5 U.S. Atherectomy Devices: Regulatory Scenario
3.6 U.S. Atherectomy Devices Market: Reimbursement Scenario
3.7 Key Clinical Trials & Studies
3.7.1 Opinions/Views on Key Clinical Trials and Their Impact on the Market and Customer
3.8 U.S. Peripheral Atherectomy: Number of Procedures
CHAPTER 4 U.S. ATHERECTOMY DEVICES MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1 U.S. Atherectomy Devices Market: Type Movement Analysis
4.2 Directional Atherectomy Devices
4.2.1 Directional atherectomy devices market, 2014 - 2025 (USD Million)
4.3 Rotational Atherectomy Devices
4.3.1 Rotational atherectomy market, 2014 - 2025 (USD Million)
4.4 Orbital Atherectomy Devices
4.4.1 Orbital atherectomy devices market, 2014 - 2025 (USD Million)
4.5 Laser Atherectomy Devices
4.5.1 Laser atherectomy devices market, 2014 - 2025 (USD Million)
CHAPTER 5 U.S. ATHERECTOMY DEVICES MARKET: END USE ESTIMATES & TREND ANALYSIS
5.1 U.S. Atherectomy Devices Market: End Use Movement Analysis
5.2 In-Patient Facility
5.2.1 In-patient facility market, 2014 - 2025 (USD Million)
5.3 Office-Based Labs (OBLs)
5.3.1 Office-based labs (OBLs) market, 2014 - 2025 (USD Million)
5.4 Out-Patient facility
5.4.1 Out-patient facility, 2014 - 2025 (USD Million)
CHAPTER 6 COMPETITIVE LANDSCAPE
6.1 Strategy Framework
6.2 Competitive Landscape: Market Position Analysis
6.3 Company Profiles
6.3.1 Boston Scientific Corporation
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 SWOT analysis
6.3.1.4 Product benchmarking
6.3.1.5 Strategic initiatives
6.3.2 Cardiovascular Systems, Inc.
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 SWOT analysis
6.3.2.4 Product benchmarking
6.3.2.5 Strategic initiatives
6.3.3 Medtronic
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 SWOT analysis
6.3.3.4 Product benchmarking
6.3.3.5 Strategic initiatives
6.3.4 Spectranetics
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 SWOT analysis
6.3.4.4 Product benchmarking
6.3.4.5 Strategic initiatives
6.3.5 Avinger
6.3.5.1 Company overview
6.3.5.2 Financial performance
6.3.5.3 Product benchmarking
6.3.5.4 Strategic initiatives
6.3.6 ST. JUDE MEDICAL
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 SWOT analysis
6.3.6.4 Product benchmarking
6.3.7 Cardinal Health (Cordis)
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 SWOT analysis
6.3.7.4 Product benchmarking
6.3.7.5 Strategic initiatives
6.3.8 Terumo Medical Corporation
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 SWOT analysis
6.3.8.4 Product benchmarking
6.3.8.5 Strategic initiatives
CHAPTER 7 RECOMMENDATIONS
7.1 KOL Views
7.2 Recommendations
LIST OF TABLES
TABLE 1 Atherectomy devices comparison
TABLE 2 Comparison of cutting balloon angioplasty vs rotational atherectomy
TABLE 3 Procedure codes and physician reimbursement for endovascular procedures, 2018
TABLE 4 Ambulatory surgery center reimbursement for endovascular procedures, 2018
TABLE 5 Medicare national average payments, 2017
TABLE 6 Medicare reimbursement by clinical setting, 2016
TABLE 7 Medicare reimbursement comparison, 2014
TABLE 8 Patient selection criteria
TABLE 9 Patient selection criteria
TABLE 10 Patient selection criteria
TABLE 11 List of in-patient facility performing atherectomy in the U.S.
TABLE 12 Top five states performing endovascular procedures including atherectomy in OBLs, 2016
TABLE 1 Atherectomy devices comparison
TABLE 2 Comparison of cutting balloon angioplasty vs rotational atherectomy
TABLE 3 Procedure codes and physician reimbursement for endovascular procedures, 2018
TABLE 4 Ambulatory surgery center reimbursement for endovascular procedures, 2018
TABLE 5 Medicare national average payments, 2017
TABLE 6 Medicare reimbursement by clinical setting, 2016
TABLE 7 Medicare reimbursement comparison, 2014
TABLE 8 Patient selection criteria
TABLE 9 Patient selection criteria
TABLE 10 Patient selection criteria
TABLE 11 List of in-patient facility performing atherectomy in the U.S.
TABLE 12 Top five states performing endovascular procedures including atherectomy in OBLs, 2016
LIST OF FIGURES
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary 2018 (USD Million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Prevalence of PAD (%) by age group (years), 2016
FIG. 12 Market restraint relevance analysis (Current &future impact)
FIG. 13 Penetration & growth prospect mapping
FIG. 14 U.S. atherectomy devices market - PESTLE analysis
FIG. 15 Porter’s Five Forces Analysis
FIG. 16 U.S. atherectomy devices market type outlook key takeaways
FIG. 17 U.S. atherectomy devices: Type movement analysis
FIG. 18 Directional atherectomy devices market, 2014 - 2025 (USD Million)
FIG. 19 Above knee atherosclerosis
FIG. 20 Below knee atherosclerosis
FIG. 21 Rotational atherectomy market, 2014 - 2025 (USD Million)
FIG. 22 Orbital atherectomy devices market, 2014 - 2025 (USD Million)
FIG. 23 Laser atherectomy devices market, 2014 - 2025 (USD Million)
FIG. 24 U.S. atherectomy devices market end-use outlook key takeaways
FIG. 25 U.S. atherectomy devices: End-use movement analysis
FIG. 26 In-patient facility market, 2014 - 2025 (USD Million)
FIG. 27 Office-based labs (OBLs) market, 2014 - 2025 (USD Million)
FIG. 28 Out-patient facility market, 2014 - 2025 (USD Million)
FIG. 29 Strategy framework
FIG. 30 U.S. atherectomy devices market: Heat map analysis
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modeling for market share assessment
FIG. 7 Market summary 2018 (USD Million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Prevalence of PAD (%) by age group (years), 2016
FIG. 12 Market restraint relevance analysis (Current &future impact)
FIG. 13 Penetration & growth prospect mapping
FIG. 14 U.S. atherectomy devices market - PESTLE analysis
FIG. 15 Porter’s Five Forces Analysis
FIG. 16 U.S. atherectomy devices market type outlook key takeaways
FIG. 17 U.S. atherectomy devices: Type movement analysis
FIG. 18 Directional atherectomy devices market, 2014 - 2025 (USD Million)
FIG. 19 Above knee atherosclerosis
FIG. 20 Below knee atherosclerosis
FIG. 21 Rotational atherectomy market, 2014 - 2025 (USD Million)
FIG. 22 Orbital atherectomy devices market, 2014 - 2025 (USD Million)
FIG. 23 Laser atherectomy devices market, 2014 - 2025 (USD Million)
FIG. 24 U.S. atherectomy devices market end-use outlook key takeaways
FIG. 25 U.S. atherectomy devices: End-use movement analysis
FIG. 26 In-patient facility market, 2014 - 2025 (USD Million)
FIG. 27 Office-based labs (OBLs) market, 2014 - 2025 (USD Million)
FIG. 28 Out-patient facility market, 2014 - 2025 (USD Million)
FIG. 29 Strategy framework
FIG. 30 U.S. atherectomy devices market: Heat map analysis
